» Articles » PMID: 27479579

[Proliferative Vitreoretinopathy: Therapeutic Strategies]

Overview
Publisher Thieme
Specialty Ophthalmology
Date 2016 Aug 2
PMID 27479579
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Development of proliferative vitreoretinopathy (PVR) is one of the most important complications of vitreoretinal surgery. Reaching the decision to treat and surgical treatment itself are both challenging.

Materials And Methods: Our own data and a review of the literature in PubMed are summarised.

Results: Pharmacological approaches to the prevention and treatment of proliferative vitreoretinopathy have been limited to concepts that have been investigated in preclinical and a few clinical studies. Anti-inflammatory and antiproliferative substances may be mentioned in this context. Surgical techniques range from scleral buckling to the gold standard pars plana vitrectomy, preferably with silicone oil endotamponade. Applying an encircling band, retinotomy or retinectomy can be useful in reattaching the tractional shortened retina.

Conclusion: Surgery is still the method of choice for the treatment of PVR. Pharmacological strategies to prevent or treat PVR have not been established.

Citing Articles

Microfluidic Fabricated Liposomes for Nutlin-3a Ocular Delivery as Potential Candidate for Proliferative Vitreoretinal Diseases Treatment.

Esposito E, Pozza E, Contado C, Pula W, Bortolini O, Ragno D Int J Nanomedicine. 2024; 19:3513-3536.

PMID: 38623081 PMC: 11018138. DOI: 10.2147/IJN.S452134.


Silicone Oil Tamponade-Retina Contact in Highly Myopic Eyes With and Without Encircling Bands: A Computational Fluid Dynamics Study.

Rossi T, Querzoli G, Badas M, Angius F, Ripandelli G Transl Vis Sci Technol. 2022; 11(6):1.

PMID: 35648638 PMC: 9172018. DOI: 10.1167/tvst.11.6.1.


Activated Blood Coagulation Factor X (FXa) Contributes to the Development of Traumatic PVR Through Promoting RPE Epithelial-Mesenchymal Transition.

Han H, Zhao X, Liao M, Song Y, You C, Dong X Invest Ophthalmol Vis Sci. 2021; 62(9):29.

PMID: 34283209 PMC: 8300057. DOI: 10.1167/iovs.62.9.29.


[Proliferative vitreoretinopathy prophylaxis : Mission (im)possible].

Schaub F, Abdullatif A, Fauser S Ophthalmologe. 2020; 118(1):3-9.

PMID: 32666172 DOI: 10.1007/s00347-020-01173-8.


[Laser flare photometry for identification of high-risk patients for proliferative vitreoretinopathy].

Schaub F, Fauser S, Kirchhof B, Witte A, Horster R Ophthalmologe. 2018; 115(12):1079-1083.

PMID: 30151741 DOI: 10.1007/s00347-018-0777-y.